CROSSJECT remains engaged during the summer break
Globenewswire·2025-08-04 15:35
Press Release CROSSJECT remains engaged during the summer break Dijon, France, August 4, 2025 (5:30 p.m. CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company developing emergency products based on its proprietary ZENEO® needle-free auto-injector technology, remains fully engaged to submitting the ZEPIZURE® dossier for Emergency Use Authorization (EUA). During the summer break, maintenance operations are being carried out at Crossject's three production sites. These wi ...